158.50
+7.09%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lin Bioscience
Its shares trade on Taipei Exchange under the ticker 6696.TWO. It has been listed since 8 October 2018. In the fiscal year to 31 December 2016, it reported revenue of TWD 190,000 and a net loss of TWD 42.2m. At that date it held total assets of TWD 526.9m and shareholders' equity of TWD 477.9m.
Lin BioScience, Inc. engages in the development of drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-10-08. The firm is in the research and development and clinical trials stage. The company has four major drugs in development, including LBS-008, LBS-007, LBS-009 and LBS-002, as well as two technical platforms of RBP4 and CDC7. LBS-008 is developed for dry macular degeneration which belongs to the best-selling drugs, and stel lesions which belongs to orphan drugs. LBS-007 is used in acute leukemia which belongs to orphan drugs, and solid tumors which belongs to the best-selling drugs. LBS-009 is used in non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and type 2 diabetes. LBS-002 is developed for primary brain cancer and metastatic brain cancer. RBP4 platform is used for metabolic diseases, and CDC7 platform is used for all cancers.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Oct 2018
- Website
- linbioscience.weebly.com ↗
Leadership
Pay as last reported
- Mr. Yu-Hsin LinChairman of the Board, since 2016
- Ms. Irene WangChief Scientific Officer, General Manager
- Ms. Serena ChenHead of Finance & Accounting
- Ms. Yvonne ChenDirector, since 2016
- Mr. Hao-Yuan ChuangDirector, since 2017
- Mr. Fangming XuDirector
- Mr. Chengwei ZhuDirector
- Mr. William LiangIndependent Director
- Mr. San-Chien TuIndependent Director
- Ms. Heidi WangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lin Bioscience has four major drugs in development including LBS-008 for dry macular degeneration and orphan drugs.
- LBS-007 targets acute leukemia and solid tumors as orphan and best-selling drugs.
- RBP4 and CDC7 platforms address metabolic diseases and all cancers respectively.
Weaknesses
- The company is in the research and development and clinical trials stage with no commercialized products.
- Lin Bioscience has no revenue from drug sales as it is still in development phase.
- LBS-009 focuses on NAFLD, NASH, and type 2 diabetes which are highly competitive markets.
Opportunities
- LBS-008 targets dry macular degeneration a best-selling drug market with high demand.
- LBS-007 addresses orphan drugs for acute leukemia with potential high pricing.
- RBP4 platform can expand into metabolic disease treatments with growing market needs.
Threats
- LBS-009 faces competition in NAFLD and NASH markets which are crowded with established players.
- The clinical trials stage for all drugs poses regulatory approval risks and delays.
- LBS-002 for brain cancer treatments faces high development costs and long timelines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.